EGFR and non-small cell lung carcinoma: Moreover, the mechanism and effect of TP53 in primary sensitivity and acquired resistance to EGFR-TKIs in NSCLC cells showed that TP53 mutations promote the epithelial-to-mesenchymal transition (EMT), activating EGFR mutations and enhancing resistance to osimertinib in H1975 cells (27).